<DOC>
	<DOCNO>NCT02733588</DOCNO>
	<brief_summary>The primary objective study test optimize control system sensor-guided ( physician administer ) delivery glucagon , test Proof-of-Concept ( POC ) clinical set patient severe hypoglycemia follow bariatric surgery .</brief_summary>
	<brief_title>Delivery G-Pump™ ( Glucagon Infusion ) From OmniPod® Prevent Hypoglycemia Post-Bariatric Surgery Patients</brief_title>
	<detailed_description>This Phase 2a , single-center , open-label , proof-of-concept study design test ability control algorithm detect direct timing G-Pump™ glucagon infuse OmniPod® pump prevent hypoglycemia patient post-bariatric hypoglycemia syndrome . While algorithm provide alert glucagon dose prevent hypoglycemia , automation clinical trial ultimately physician initiate dose via OmniPod® controller . Participant continuous glucose monitor arrive clinic IV line insert venous access . Subject ask drink liquid mixed meal contain 60 g carbohydrate , e.g . Boost® Nutritional Drink , 10 minute . Blood sample collect glucose hormone measurement . The open-loop system set recognize low sensor glucose value , trigger alert physician , deliver bolus 150 300 µg glucagon via pump , goal prevent decline glucose value . Depending response , second bolus dose 150 300 µg glucagon may administer . Plasma glucose measure glucagon administration ensure successful treatment glucose stability , glucagon level analyze concurrently determine magnitude increase baseline . Sensors download subsequent analysis appropriateness alert time trigger glucagon bolus delivery .</detailed_description>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>diagnose ongoing postbariatric hypoglycemia prior episodes neuroglycopenia , unresponsive dietary intervention ( low glycemic index , control carbohydrate portion ) trial acarbose therapy maximally tolerate dose . willingness provide inform consent follow study procedure , include attend schedule visit . document hypoglycemia occur fast state ( &gt; 12 hour fast ) ; chronic kidney disease stage 4 5 ; hepatic disease , include serum alanine aminotransferase aspartate aminotransferase great equal 3 time upper limit normal ; hepatic synthetic insufficiency define serum albumin &lt; 3.0 g/dL ; serum bilirubin &gt; 2.0 ; congestive heart failure , New York Heart Association class II , III IV ; history myocardial infarction , unstable angina revascularization within past 6 month ; history cerebrovascular accident ; seizure disorder ( suspect document hypoglycemia ) ; active treatment diabetes medication except acarbose ; active malignancy , except basal cell squamous cell skin cancer ; personal family history pheochromocytoma disorder increase risk pheochromocytoma ( MEN 2 , neurofibromatosis , Von HippelLindau disease ) ; know insulinoma ; major surgical operation within 30 day prior screen ; hematocrit ≤ 33 % ; bleed disorder , treatment warfarin , platelet count &lt; 50,000 ; blood donation ( 1 pint whole blood ) within past 2 month ; active alcohol abuse substance abuse ; current administration oral parenteral corticosteroid ; pregnancy and/ Lactation : For woman childbearing potential : requirement negative urine pregnancy test agreement use contraception study least 1 month participate study . use investigational drug within 30 day prior screen . involvement special vulnerable population pregnant woman , prisoner , institutionalize incarcerated individual , others may consider vulnerable population .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>hypoglycemia</keyword>
	<keyword>glucagon</keyword>
	<keyword>glucose metabolism disorder</keyword>
	<keyword>hormone</keyword>
	<keyword>gastrointestinal agent</keyword>
	<keyword>bariatric surgery</keyword>
	<keyword>incretins</keyword>
</DOC>